Biotech Small-Cap M&A Cycle: Post-Approval Takeout Window and RAS Proxy Mispricing

Executive Summary

Seedy19, a self-taught full-time biotech investor, generated a 35-fold return on his entire portfolio in 2025 using common stock, covered calls, and put writing — no long calls. His framework centers on identifying catalysts where market pricing implies a binary outcome that historical precedent or blinded trial data contradicts. Two names he discusses as current positions are Vera Therapeutics (VERA) and Erasca (ERAS). VERA received FDA approval for its IgA nephropathy drug with a clean label, placing it inside the historical three-to-twelve-month post-approval window where pharma bolt-on acquisitions are most common. At roughly $42 and a $3 billion market cap, the stock sits well below its 52-week high of $56. ERAS is framed as a proxy trade on the RAS/PanRAS oncology niche dominated by Revolution Medicines (RVMD), which trades at approximately $193 and a $39.7 billion market cap with zero revenue. Seedy argues ERAS deserves roughly one-quarter of RVMD's valuation given a similar molecule and potentially superior safety and durability profile. Material risks temper both ideas: VERA shows light insider selling by a senior executive, and ERAS carries an active class action lawsuit and a bearish news sentiment score of -0.57. RVMD itself, the valuation anchor for the ERAS thesis, shows heavy net insider selling of approximately $39 million over ninety days, which weakens the comparative argument. The broader process insight — monitoring specialist biotech hedge fund 13F filings, tracking proxy molecules after large-cap M&A events, and using AI to translate clinical data — is the most durable takeaway for generalist investors entering the space.

Key Insights